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Abstract 
A series of new quinazolines linked to triazoles through an ether chain in position 2 has been designed and 
synthetized through a flexible route. Cytotoxicity assays on selected cancer cell lines and inhibition studies 
toward a panel of representative mammalian kinases have been performed on these molecules. 
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Introduction 
 
Many quinazoline alkaloids and derivatives have been isolated already, and the antimalarial (+)- Febrifugine 1 
and the cytotoxic Luotonin A 2 are representative examples of this family of natural products (Figure 1).1 From 
a structural point of view, almost all of them possess a quinazoline-4(3H)-one ring system. On the other hand, 
the quinazoline nucleus is also a privilege scaffold found in the basic skeleton of various types of drugs and/or 
bioactive molecules.2-4 Representative examples are indicated in Figure 1 and it is worth noting that all 
compounds 3-8, which are potent kinase inhibitors used as anticancer drugs, have an aniline-type substituent 
in position 4 of this structure. Some other quinazolines, like Doxasocine 9 and Prazosin 10 (these two 
derivatives are used against hypertension) have both a primary amine in position 4 and a substituted 
piperazine in position 2. 
 
 
 
Figure 1. Representative examples of bioactive natural products and drugs with quinazoline cores. 
 
Further, extensive literature search shows that much less is known about type-A molecules with X-R1 
chains in position 2 (X being heteroatom like O, S and N and R1= alkyl or substituted alkyl chains, aromatics, 
heteroaromatics…..) (Figure 2). Therefore, we embarked on a program involving the synthesis and biological 
evaluation of such derivatives. The goal of this paper is to report the first part of this research, dealing with the 
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synthesis of a focused library of oxygen-linked molecules 11 with a short linker and triazoles in terminal 
position. The choice of the triazole nucleus is based upon the fact that this core structure is found also in many 
biologically active molecules. 5     
 
 
 
Figure 2. Our target molecules. 
 
 
Results and Discussion 
 
Chemical synthesis 
Various strategies and disconnections have been reported for the synthesis of quinazolines.6-7 In our case we 
favored the approach through two C-N bond disconnections and starting from an ortho-aminobenzaldehyde 
derivative 13 (Scheme 1). Reaction with urea gave in good yield quinazoline 14 which was further treated by 
POCl3 to give chloroquinazoline 14a. This intermediate was reacted with propargyl alcohol to isolate in 65% 
yield propargyl ether 15. Final click-type reactions,8-11 with various azido derivatives 16a-j,12 afforded the 
target molecules 11a-j in good yields (Table1). 
 
 
 
Scheme 1. Synthesis of quinazoline-based triazoles. 
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Table 1. Synthesis of our target molecules 
Entry  n R2 Molecule Yield % 
1 0 4-MeO 11a 75 
2 0 4-Cl 11b 65 
3 0 2-Cl 11c 64 
4 0 2-MeO 11d 68 
5 0 3-MeO 11e 71 
6 0 4-Br 11f 64 
7 0 H 11g 74 
8 1 H 11h 74 
9 1 4-NO2 11i 50 
10 1 2,6-di-Cl 11j 60 
 
All intermediates and final products have spectral and analytical data in agreement with their structures.  
 
Biological studies 
Based on the known biological properties of molecules with quinazoline scaffolds, we performed a few 
primary biological screenings of the ten molecules 11a-11j.  
First, their cytotoxicity has been checked on seven representative cancer cell lines (HuH7, CaCo-2, MDA-
MB231, HCT116, PC3, NCI-H727, MCF7). All compounds were found to be devoid of any significant cytotoxicity 
at 10 M concentration (See Supplementary Material).  
Their activity was also screened against a panel of eight representative kinases (HsCDK5/p25, 
HsCDK9/CyclinT, HsPIM1, MmCLK1, RnDYRK1A, HsHASPIN, HsGSK3β, HsCK1ε) and the results are reported in 
Table 2. Interestingly only one of these kinases (MmCLK1) was found to be responding to these derivatives. A 
few molecules (11a, 11c, 11d, 11e, 11f, 11j) exhibited a moderate inhibition of this kinase at 10M. On the 
other hand, these molecules were found to be devoid of any significant activity at 10M concentration on the 
other kinases. 
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Table 2. Study of the inhibition of quinazolines 11 against a representative panel of mammalian kinases 
Compound  Concentration HsCDK5/ 
p25 
HsCDK9/ 
CyclinT 
HsPIM1 MmCLK1 RnDYRK1A HsHASPIN HsGSK3β HsCK1ε 
11a 10 µM 104 87 95 63 104 99 87 108 
1 µM 109 90 125 102 109 99 89 95 
11b 10 µM 118 89 125 105 98 97 86 121 
1 µM 135 82 97 101 105 87 74 90 
11c 10 µM 124 86 78 44 88 80 72 101 
1 µM 110 79 94 102 107 105 87 99 
11d 10 µM 120 104 91 49 103 113 90 96 
1 µM 106 92 100 98 98 109 86 97 
11e 10 µM 101 103 99 26 98 111 78 87 
1 µM 109 94 100 84 77 100 93 87 
11f 10 µM 79 110 98 48 117 114 105 105 
1 µM 111 128 111 100 76 103 89 96 
11g 10 µM 113 101 105 106 110 112 100 97 
1 µM 98 97 100 87 93 88 94 94 
11h 10 µM 112 112 106 74 100 116 103 116 
1 µM 114 119 120 99 94 92 78 81 
11i 10 µM 116 128 121 109 144 118 110 113 
1 µM 104 106 110 108 81 108 63 79 
11j 10 µM 121 121 116 67 100 90 67 95 
1 µM 113 85 127 129 84 98 55 61 
 
Percentages of residual kinase activity were determined at 1 and 10 M concentration for each compound. 
Kinase activities were assayed in duplicate.  
 
 
Conclusions 
 
In summary, we designed a short and convergent strategy toward the desired quinazolines linked to triazoles 
through an ether chain in position 2 of the quinazoline. Some of these derivatives exhibit a moderate, but 
significant and selective, activity against the MmCLK1 kinase. Extension of this approach to other quinazoline-
derived derivatives is under active study and will be reported in due course. 
 
 
Experimental Section 
 
Chemical Synthesis 
 
General. All anhydrous reactions were performed in heat gun-dried round-bottomed flasks under a dry argon 
or nitrogen atmosphere. Air and moisture-sensitive compounds were introduced via syringes or cannula, using 
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standard inert atmosphere techniques. In addition, the gas stream was passed through glass cylinder filled 
with P2O5 to remove any traces of residual moisture. Reactions were monitored by thin layer chromatography 
(TLC) using E. Merck silica gel plates and components were visualized by illumination with short wavelength 
UV light and/or staining (Ninhydrin or basic KMnO4). THF and Et2O were dried over sodium-benzophenone and 
distilled prior to use. Anhydrous CH2Cl2 was prepared by refluxing in the presence of CaH2 and distilled right 
before use unless otherwise noted. Infrared spectra have been recorded on a Bruker alpha II FTIR 
spectrometer. 1H NMR spectra were recorded at 300 and 400 MHz, and 13C NMR spectra at 75 and 100 MHz,in 
CDCl3 or DMSO-d6 using tetramethylsilane (TMS) as an internal standard on Bruker spectrometers (Avance 
300III and Avance 300I and AvanceIII 400). Assignments were made using standard 2D NMR techniques (COSY, 
HMQC/HSQC, HMBC). High resolution mass spectra were performed using a time of flight Maxis 4G (Bruker 
Daltonik Gmbh, Bremen, Germany) in Electrospray positive ionization mode. LC-MS analyses were carried out 
on a Shimadzu [LCMS-2020], SHIMPAK, XR ODS-II column (50 x 2 mm) utilizing the following method. Solvent A 
= Acetonitrile, B = 0.1% TFA in water; Initial 95% of solvent B, then run gradient, which should reach 90% 
solvent A within 10 min and hold 90% solvent A for another 10 min. Flow Rate: 0.2 ml/min. 
 
Synthesis of 2-amino-3-methoxybenzaldehyde (13). To a stirred solution of 3-methoxy-2-nitrobenzaldehyde 
(12) (10 g, 54 mmol) in a mixture of methanol (100 mL) and glacial acetic acid (100 mL) and water (50 mL) was 
added reduced iron powder (16 g, 144 mmol) in lot wise manner. The resulting suspension was stirred at 30-
35oC for 2h. The reaction mixture was filtered on Celite bed and washed with methanol (50 mL). The filtrate 
was concentrated to remove volatiles and it was partitioned between sat. NaHCO3 (150 mL) and ethyl acetate 
(200 mL). The basic layer was further extracted with ethyl acetate (100 mL). The combined organic extracts 
were washed with brine (50 mL), dried over Na2SO4 and concentrated to dryness and purified by 
chromatography on silica gel eluting with 20% EtOAc in hexane giving a compound 13 (6.5 g, 78% Yield) as a 
off white solid. 1H NMR (400 MHz, CDCl3) δ ppm: 9.93 (s, 1H), 8.45 (d, 1H), 7.82 (d, 1H), 6.80 (t, 1H); Mass 
(m/z): 165.2 (M+H). 
Synthesis of 8-methoxyquinazolin-2-ol (14). 2-Amino-3-methoxybenzaldehyde (13) (5 g, 33.1 mmol), urea (20 
g, 336.3 mmol) and cat. NH4OAc (10 mg) were thoroughly mixed together in a round bottom flask. The solid 
mixture was heated to 160 oC and the solids quickly melted and stirring was continued for 15 min. A solid 
started to precipitate from the hot solution, NMP (25 mL) was added to dissolve the solids, the reaction was 
heated with stirring for an additional 2 h at 155-160 oC. The hot reaction mixture was poured into vigorously 
stirred ice water (150 mL).The reaction mixture was filtered, washed with water (50 mL) and ethyl acetate (15 
mL) giving a brown color solid which was dried to give compound 14 (4.9 g, 82% yield) as a off white solid. 1H 
NMR (500 MHz, DMSO-d6) δ ppm: 11.3 (br, 1H), 9.23 (s, 1H), 7.43 (t, 1H), 7.34 (d, 2H), 3.90 (s, 3H); Mass (m/z): 
177.2 (M+H) 
Synthesis of 2-chloro-8-methoxyquinazoline (14a). A mixture of compound 14 (4 g, 22 mmol) and 2,3,5-
collidine (5 mL, 38.8 mmol) in acetonitrile (80 mL) was stirred at room temperature for 10 min. POCl3 (22 mL, 
222 mmol) was added to reaction mixture at 0 oC and the reaction mixture was heated for 10 h at reflux. The 
mixture was concentrated to dryness. The obtained residue was partitioned between EtOAc (200 mL) and sat. 
NaHCO3 (200 mL). The mixture was stirred cautiously watching gas evolution until the pH reached to 8. The 
layers were separated and the organic layer was washed with sat. NaHCO3 (75 ml), brine (50ml), dried 
(Na2SO4), and concentrated to dryness, giving compound 14a (2.8 g, 63.5% yield) as a pale yellow solid. 1H 
NMR (400 MHz, CDCl3) δ ppm: 9.25 (s, 1H), 7.61-7.57 (t, J 16.0 Hz, 1H), 7.51-7.48 (t, J 8.4, 1H), 7.28 (dd, J 8.0, 
0.8 Hz, 1H), 4.07 (s, 3H); 13C NMR (400 MHz, CDCl3): δ 162.72, 156.93, 154.08, 143.80, 128.59, 124.33, 118.41, 
113.08, 56.26. Mass (m/z): 195.1 (M+H). 
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Synthesis of 8-methoxy-2-(prop-2-yn-1-yloxy)quinazoline (15). Propargyl alcohol (518 mg, 9.24 mmol) was 
added to a stirred suspension of Cs2CO3 (3g, 9.24 mmol) and DMF (10 mL), after stirring 15 minutes at 30 oC 
compound 14a (600 mg, 3.08 mmol) was added. After stirring at 100 oC for 16h, the reaction mixture was 
quenched with water (30 mL) and extracted with DCM (2x25 mL). The combined organic extracts were washed 
with brine (5%, 15 mL), dried over Na2SO4 and concentrated to dryness. Purification by chromatography on 
silica gel (elution with EtOAc in hexane) gave compound 15 (450 mg, 65% yield) as a off white solid. 1H NMR 
(400 MHz, CDCl3) δ ppm: 9.23 (s, 1H), 7.46-7.38 (m, 2H), 7.21 (d, J 7.6, 1.6 Hz, 1H), 5.21 (s, 2H), 4.06 (s, 3H), 
2.49 (t, J 2.4 Hz, 1H); 13C NMR (400 MHz, CDCl3): δ 163.62, 161.11, 153.84, 143.67, 125.43, 122.96, 118.90, 
113.06, 78.55, 74.63, 56.33, 55.18. Mass (m/z): 215.1 (M+H). 
 
General procedure for preparation of compounds, 11a-j. To the stirred solution of compound 15 (0.1 mmol, 
1.0 eq.) and compound 16a-j [prepared using general protocol,12 (0.1 mmol, 1 eq.) in a 1:1 mixture of t-butanol 
and water (0.56 mL) was added copper sulfate pentahydrate (0.01 mmol, 0.1 eq.) and sodium ascorbate (0.03 
mmol, 0.3 eq.) at room temperature. The resulting mixture was stirred for overnight. After completion of the 
reaction, it was diluted with a mixture of ethyl acetate and water (7.5 ml in a 1:1 ratio), the organic layer was 
separated and washed with 5% ammonium hydroxide solution (0.5 mL) and followed by brine (0.5 mL). The 
combined organic layers were dried over Na2SO4. The solvents were evaporated under reduced pressure to 
get the crude product, which was purified by chromatography on silica gel affording target compounds 11a-j 
(65-75% yield) as light yellow to brown solids. 
8-Methoxy-2-((1-(4-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazoline (11a). Reaction of 15 (25 mg, 
0.11 mmol) with 16a (17.4 mg, 0.11 mmol) gave 11a: 31.6 mg, 75% yield. mp 179-181 °C; FT-IR (KBr, cm-1): 
3137, 2958, 2841, 1584, 1516, 1470, 1419, 1292, 1261, 1175, 1117, 1034, 836, 763. 1H NMR (300 MHz, CDCl3): 
δ 9.23 (s, 1H, H-quinazoline), 8.37 (br t, J 0.5 Hz, 1H, H-triazole), 7.62 (half part of an A2X2 system, 2H meta to 
OMe), 7.46 (dd, J 8.1, 1.6 Hz, 1H, H-C7 of quinazoline), 7.40 (dd, J 8.1, 7.4 Hz, 1H, H-C6 of quinazoline), 7.22 
(ddd, J 7.4, 1.6, 0.2 Hz, 1H, H-C5 of quinazoline), 7.01 (half part of an A2X2 system, 2H ortho to OMe), 5.80 (d, J 
0.5 Hz, 2H, CH2), 4.09 (s, 3H, CH3, OMe on quinazoline), 3.86 (s, 3H, CH3, OMe of 4-methoxyphenyl). 13C NMR 
(75 MHz, CDCl3): δ 163.72 (CH, α to N of quinazoline), 161.65 (C, C2 of quinazoline), 159.81 (C, α to OMe), 
153.83 (C, C8 of quinazoline), 144.19 (C of triazole), 143.59 (C, C8a of quinazoline), 130.67 (C, δ to OMe), 
125.28 (CH, C6 of quinazoline), 122.92 (CH of triazole), 122.89 (C, C4a of quinazoline), 122.15 (2CH, meta to 
OMe), 118.99 (CH, C7 of quinazoline), 114.78 (2CH, ortho to OMe), 112.87 (CH, C5 of quinazoline), 61.33 (CH2), 
56.23 (CH3, OMe on quinazoline), 55.64 (CH3, OMe of 4-methoxyphenyl). LC-MS: 363.13 [M]. HRMS–ESI (m/z) 
[M+Na]+ calcd for C19H17N5NaO3: 386.12236, found 386.1222, [M+K]+ calcd for C19H17KN5O3: 402.09630, found 
402.0957. 
2-((1-(4-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-8-methoxyquinazoline (11b). Reaction of 15 (25 mg, 
0.11 mmol) with 16b (17.92 mg, 0.11 mmol) gave 11b: 28 mg, 65% yield. mp 130 °C (dec); FT-IR (KBr, cm-1): 
3339, 3332, 2999, 1581, 1493, 1421, 1382, 1293, 1171, 1108, 1029, 830, 756.  1H NMR (400 MHz, CDCl3): δ 
9.24 (s, 1H, H-quinazoline), 8.47 (s, 1H, H-triazole), 7.68 (half part of an A2X2 system, 2H meta to Cl), 7.49 (half 
part of an A2X2 system, 2H ortho to Cl), 7.46 (dd, J 8.2, 1.4 Hz, 1H, H-C7 of quinazoline), 7.42 (dd, J 8.2, 7.5 Hz, 
1H, H-C6 of quinazoline), 7.23 (dd, J 7.6, 1.4 Hz, 1H, H-C5 of quinazoline), 5.80 (d, J 0.6 Hz, 2H, CH2), 4.10 (s, 
3H, CH3, OMe), 13C NMR (100 MHz, CDCl3): δ 163.77 (CH, α to N of quinazoline), 161.58 (C, C2 of quinazoline), 
153.80 (C, C8 of quinazoline), 144.68 (C of triazole), 143.53 (C, C8a of quinazoline), 135.66 (C, δ to Cl), 134.50 
(C, α to Cl), 129.94 (2CH, ortho to Cl), 125.36 (CH, C6 of quinazoline), 122.91 (C, C4a of quinazoline), 122.77 
(CH of triazole), 121.65 (2CH, meta to Cl), 119.04 (CH, C7 of quinazoline), 112.93 (CH, C5 of quinazoline), 61.17 
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(CH2), 56.23 (CH3, OMe). LC-MS: 367.79 [M]. HRMS–ESI (m/z) [M+Na]+ calcd for C18H1435ClN5NaO2: 390.07282, 
found 390.0726, [M+K]+ calcd for C18H1435ClKN5O2: 406.04676, found 406.0460. 
2-((1-(2-Chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-8-methoxyquinazoline (11c). Reaction of 15 (20 mg, 
0.093 mmol) with 16c (14.28 mg, 0.11 mmol) gave 11c: 22.1 mg, 64% yield. mp 134-136 °C; FT-IR (KBr, cm-1): 
3146, 3004, 1580, 1486, 1417, 1382, 1288, 1168, 1119, 1022, 757, 665.  1H NMR (300 MHz, CDCl3): δ 9.23 (s, 
1H, H-quinazoline), 8.48 (br t, J 0.5 Hz, 1H, H-triazole), 7.66-7.59 (m, 1H, H-4 of 2-chlorophenyl), 7.59-7.53 (m, 
1H, H-5 of 2-chlorophenyl), 7.48-7.40 (m, 3H, H-3 and H-6 of 2-chlorophenyl and H-C7 of quinazoline), 7.40 
(dd, J 8.1, 7.4 Hz, 1H, H-C6 of quinazoline), 7.20 (dd, J 7.4, 1.6 Hz, 1H, H-C5 of quinazoline), 5.84 (d, J 0.5 Hz, 
2H, CH2), 4.06 (s, 3H, CH3, OMe). 13C NMR (75 MHz, CDCl3): δ 163.74 (CH, α to N of quinazoline), 161.54 (C, C2 
of quinazoline), 153.73 (C, C8 of quinazoline), 143.42 (C, C8a of quinazoline), 143.32 (C of triazole), 134.93 (C, 
α to Cl), 130.75 (CH, C5 of 2-chlorophenyl), 130.62 (CH, C6 of 2-chlorophenyl), 128.29 (C, C1 of 2-
chlorophenyl), 127.94 (CH, C3 of 2-chlorophenyl), 127.76 (CH, C4 of 2-chlorophenyl), 126.89 (CH of triazole), 
125.29 (CH, C6 of quinazoline), 122.80 (C, C4a of quinazoline), 118.90 (CH, C7 of quinazoline), 112.70 (CH, C5 
of quinazoline), 61.03 (CH2), 56.13 (CH3, OMe). LC-MS: 367.79 [M]. HRMS–ESI (m/z) [M+Na]+ calcd for 
C18H1435ClN5NaO2: 390.07282, found 390.0729, [M+K]+ calcd for C18H1435ClKN5O2: 406.04676, found 406.0462, 
[M+H]+ calcd for C18H1535ClN5O2: 368.09088, found 368.0904. 
8-Methoxy-2-((1-(2-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazoline (11d). Reaction of 15 (25 mg, 
0.11 mmol) with 16d (17.4 mg, 0.11 mmol) gave 11d: 29.4 mg, 68% yield. mp 147-149 °C; FT-IR (KBr, cm-1): 
3157, 2963, 2838, 1580, 1470, 1417, 1286, 1170, 1119, 1017, 753, 668.  1H NMR (300 MHz, CDCl3): δ 9.23 (s, 
1H, H-quinazoline), 8.44 (br t, J 0.6 Hz, 1H, H-triazole), 7.77 (ddd, J 7.8, 1.7, 0.3 Hz, 1H, H6 of 2-
methoxyphenyl), 7.45 (dd, J 8.2, 1.5 Hz, 1H, H-C7 of quinazoline), 7.41 (ddd, J 8.2, 7.6, 1.7 Hz, 1H, H-C6 of 
quinazoline), 7.39 (dd, J 8.1, 7.4 Hz, 1H, H4 of 2-methoxyphenyl), 7.20 (br dd, J 7.5, 1.5 Hz, 1H, H-C5 of 
quinazoline), 7.09 (td, J 7.7, 1.3 Hz, 1H, H5 of 2-methoxyphenyl), 7.07 (br dd, J 8.3, 1.1 Hz, 1H, H3 of 2-
methoxyphenyl), 5.84 (d, J 0.6 Hz, 2H, CH2), 4.07 (s, 3H, CH3, OMe on quinazoline), 3.84 (s, 3H, CH3, OMe of 2-
methoxyphenyl). 13C NMR (75 MHz, CDCl3): δ 163.63 (CH, α to N of quinazoline), 161.70 (C, C2 of quinazoline), 
153.85 (C, C8 of quinazoline), 151.23 (C α to OMe of 2-methoxyphenyl), 143.69 (C, C8a of quinazoline), 143.03 
(C of triazole), 130.04 (CH, C4 of 2-methoxyphenyl), 126.47 (CH of triazole), 126.41 (C, C1 of 2-methoxyphenyl), 
125.62 (CH, C6 of 2-methoxyphenyl), 125.20 (CH, C6 of quinazoline), 122.85 (C, C4a of quinazoline), 121.22 
(CH, C5 of 2-methoxyphenyl), 118.94 (CH, C7 of quinazoline), 112.83 (CH, C5 of quinazoline), 112.27 (CH, C3 of 
2-methoxyphenyl), 61.38 (CH2), 56.23 (CH3, OMe on quinazoline), 55.94 (CH3, OMe of 2-methoxyphenyl). LC-
MS: 363.13 [M]. HRMS–ESI (m/z) [M+Na]+ calcd for C19H17N5NaO3: 386.12236, found 386.1228, [M+K]+ calcd 
for C19H17KN5O3: 402.09630, found 402.0963, [M+H]+ calcd for C19H18N5O3: 364.14041, found 364.1404. 
8-Methoxy-2-((1-(3-methoxyphenyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazoline (11e). Reaction of 15 (25 mg, 
0.11 mmol) with 16e (17.4 mg, 0.11 mmol) gave 11e: 30 mg, 71% yield. mp 137-139 °C; FT-IR (KBr, cm-1): 3144, 
3002, 1594, 1483, 1420, 1289, 1165, 1015, 1031, 855, 764.  1H NMR (300 MHz, CDCl3): δ 9.23 (s, 1H, H-
quinazoline), 8.48 (br t, J 0.6 Hz, 1H, H-triazole), 7.46 (dd, J 8.2, 1.6 Hz, 1H, H-C7 of quinazoline), 7.44-7.36 (m, 
2H, H-C6 of quinazoline at 7.43 ppm and H5 of 3-methoxyphenyl at 7.39 ppm), 7.34 (dd, J 2.4, 2.1 Hz, 1H, H2 of 
3-methoxyphenyl), 7.26 (ddd, J 8.0, 2.1, 1.0 Hz, 1H, H6 of 3-methoxyphenyl), 7.23 (br dd, J 7.5, 1.6 Hz, 1H, H-C5 
of quinazoline), 6.96 (ddd, J 8.3, 2.5, 1.0 Hz, 1H, H4 of 3-methoxyphenyl), 5.81 (d, J 0.5 Hz, 2H, CH2), 4.10 (s, 
3H, CH3, OMe on quinazoline), 3.87 (s, 3H, CH3, OMe of 3-methoxyphenyl). 13C NMR (75 MHz, CDCl3): δ 163.74 
(CH, α to N of quinazoline), 161.63 (C, C2 of quinazoline), 160.64 (C, α to OMe of 3-methoxyphenyl), 153.83 (C, 
C8 of quinazoline), 144.34 (C of triazole), 143.56 (C, C8a of quinazoline), 138.20 (C, C1 of 3-methoxyphenyl), 
130.49 (CH, C5 of 3-methoxyphenyl), 125.30 (CH, C6 of quinazoline), 122.96 (CH of triazole), 122.90 (C, C4a of 
quinazoline), 119.00 (CH, C7 of quinazoline), 114.60 (CH, C4 of 3-methoxyphenyl), 112.88 (CH, C5 of 
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quinazoline), 112.33 (CH, C6 of 3-methoxyphenyl), 106.31 (CH, C2 of 3-methoxyphenyl), 61.27 (CH2), 56.24 
(CH3, OMe on quinazoline), 55.64 (CH3, OMe of 3-methoxyphenyl). LC-MS: 363.13 [M]. HRMS–ESI (m/z) 
[M+Na]+ calcd for C19H17N5NaO3: 386.12236, found 386.1277, [M+K]+ calcd for C19H17KN5O3: 402.09630, found 
402.0962. 
2-((1-(4-Bromophenyl)-1H-1,2,3-triazol-4-yl)methoxy)-8-methoxyquinazoline (11f):. Reaction of 15 (25 mg, 
0.11 mmol) with 16f (23.1 mg, 0.11 mmol) gave 11f: 31 mg, 64% yield. mp 144-146 °C; FT-IR (KBr, cm-1): 3061, 
3007, 1581, 1491, 1418, 1291, 1172, 1024, 829, 762. 1H NMR (400 MHz, CDCl3): δ 9.24 (s, 1H, H-quinazoline), 
8.47 (br t, J 0.6 Hz, 1H, H-triazole), 7.67-7.60 (symmetrical m, 4H of 4-bromophenyl), 7.47 (dd, J 8.1, 1.4 Hz, 1H, 
H-C7 of quinazoline), 7.42 (dd, J 8.1, 7.5 Hz, 1H, H-C6 of quinazoline), 7.23 (dd, J 7.6, 1.3 Hz, 1H, H-C5 of 
quinazoline), 5.80 (br d, J 0.6 Hz, 2H, CH2), 4.10 (s, 3H, CH3, OMe). 13C NMR (100 MHz, CDCl3): δ 163.78 (CH, α 
to N of quinazoline), 161.57 (C, C2 of quinazoline), 153.79 (C, C8 of quinazoline), 144.70 (C of triazole), 143.51 
(C, C8a of quinazoline), 136.13 (C, δ to Br), 132.91 (2CH, ortho to Br of 4-bromophenyl), 125.36 (CH, C6 of 
quinazoline), 122.91 (C, C4a of quinazoline), 122.73 (CH of triazole), 122.34 (C, α to Br), 121.88 (2CH, meta to 
Br of 4-bromophenyl), 119.07 (CH, C7 of quinazoline), 112.92 (CH, C5 of quinazoline), 61.17 (CH2), 56.23 (CH3, 
OMe). LC-MS: 412.24 [M]. HRMS–ESI (m/z) [M+Na]+ calcd for C18H1479BrN5NaO2: 434.02231, found 434.0225, 
[M+K]+ calcd for C18H1479BrKN5O2: 449.99624, found 449.9959. 
8-Methoxy-2-((1-phenyl-1H-1,2,3-triazol-4-yl)methoxy)quinazoline (11g).  
Reaction of 15 (25 mg, 0.11 mmol) with 16g (13.90 mg, 0.11 mmol) gave 11g: 29.1 mg, 74% yield. mp 168-170 
°C; FT-IR (KBr, cm-1): 3143, 3070, 3003, 1585, 1484, 1418, 1292, 1171, 1117, 1030, 764, 690.  1H NMR (400 
MHz, CDCl3): δ 9.24 (s, 1H, H-quinazoline), 8.48 (s, 1H, H-triazole), 7.76-7.71 (m, 2H, H ortho of Ph), 7.55-7.49 
(m, 2H, H meta of Ph), 7.48-7.38 (m, 3H, H-C6 of quinazoline, H-C7 of quinazoline and H para of Ph), 7.23 (dd, J 
7.6, 1.3 Hz, 1H, H-C5 of quinazoline), 5.82 (s, 2H, CH2), 4.10 (s, 3H, CH3, OMe). 13C NMR (75 MHz, CDCl3): δ 
163.74 (CH, α to N of quinazoline), 161.64 (C, C2 of quinazoline), 153.83 (C, C8 of quinazoline), 144.40 (C of 
triazole), 143.57 (C, C8a of quinazoline), 137.20 (C ipso of Ph), 129.74 (2CH, meta of Ph), 128.69 (CH, para of 
Ph), 125.30 (CH, C6 of quinazoline), 122.90 (CH of triazole), 122.85 (C, C4a of quinazoline), 120.52 (2CH, ortho 
of Ph), 119.01 (CH, C7 of quinazoline), 112.88 (CH, C5 of quinazoline), 61.28 (CH2), 56.22 (CH3, OMe). LC-MS: 
333.3 [M]. HRMS–ESI (m/z) [M+Na]+ calcd for C18H15N5NaO2: 356.11179, found 356.1121, [M+K]+ calcd for 
C18H15KN5O2: 372.08573, found 372.0856. 
2-((1-Benzyl-1H-1,2,3-triazol-4-yl)methoxy)-8-methoxyquinazoline (11h). Reaction of 15 (20 mg, 0.093 mmol) 
with 16h (12.38 mg, 0.093 mmol) gave 11h: 24.2 mg, 74% yield. mp 109-111 °C; FT-IR (KBr, cm-1): 3006, 1579, 
1468, 1414, 1280, 1166, 1117, 1002, 816, 742. 1H NMR (300 MHz, CDCl3): δ 9.19 (s, 1H, H-quinazoline), 7.84 (s, 
1H, H-triazole), 7.43 (dd, J 8.1, 1.4 Hz, 1H, H-C7 of quinazoline), 7.39 (dd, J 8.1, 7.5 Hz, 1H, H-C6 of quinazoline), 
7.37-7.32 (m, 3H, 2H meta and 1H para of benzyl), 7.29-7.23 (m, 2H, 2H ortho of benzyl), 7.18 (dd, J 7.5, 1.3 
Hz, 1H, H-C5 of quinazoline), 5.71 (s, 2H, CH2 between O and triazole), 5.52 (s, 2H, CH2 of benzyl), 3.99 (s, 3H, 
CH3, OMe). 13C NMR (75 MHz, CDCl3): δ 163.63 (CH, α to N of quinazoline), 161.52 (C, C2 of quinazoline), 
153.71 (C, C8 of quinazoline), 144.07 (C of triazole), 143.49 (C, C8a of quinazoline), 134.54 (C ipso of Ph), 
129.09 (2CH, meta of benzyl), 128.73 (CH, para of benzyl), 128.15 (2CH, ortho of benzyl), 125.24 (CH, C6 of 
quinazoline), 124.19 (CH of triazole), 122.77 (C, C4a of quinazoline), 118.89 (CH, C7 of quinazoline), 112.72 
(CH, C5 of quinazoline), 61.32 (CH2 between O and triazole), 56.12 (CH3, OMe), 54.19 (CH2 of benzyl). LC-MS: 
347.37 [M]. HRMS–ESI (m/z) [M+Na]+ calcd for C19H17N5NaO2: 370.12744, found 370.1277, [M+K]+ calcd for 
C19H17KN5O2: 386.10138, found 386.1013. 
8-Methoxy-2-((1-(4-nitrobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)quinazoline (11i). Reaction of 15 (20 mg, 
0.093 mmol) with 16i (16.56 mg, 0.093 mmol) gave 11i: 18.4 mg, 50% yield. mp 179-181 °C; FT-IR (KBr, cm-1): 
3132, 3008, 1692, 1586, 1519, 1471, 1416, 1342, 1290, 1169, 1117, 1016, 756. 1H NMR (400 MHz, DMSO-d6): δ 
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9.43 (s, 1H, H-quinazoline), 8.41 (s, 1H, H-triazole), 8.21 (half part of an A2X2 system, 2H ortho to NO2 of 4-
nitrobenzyl), 7.62 (dd, J 8.1, 1.3 Hz, 1H, H-C7 of quinazoline), 7.53 (half part of an A2X2 system with small 
coupling with CH2, 2H meta to NO2 of 4-nitrobenzyl), 7.48 (dd, J 8.0, 7.9 Hz, 1H, H-C6 of quinazoline), 7.40 (dd, 
J 7.9, 1.2 Hz, 1H, H-C5 of quinazoline), 5.81 (s, 2H, CH2 of 4-nitrobenzyl), 5.55 (s, 2H, CH2 between O and 
triazole), 3.96 (s, 3H, CH3, OMe). 13C NMR (100 MHz, DMSO-d6): δ 164.22 (CH, α to N of quinazoline), 160.86 
(C, C2 of quinazoline), 153.11 (C, C8 of quinazoline), 147.14 (C, α to NO2), 143.28 (C para to NO2 of 4-
nitrobenzyl), 142.70 (C of triazole), 142.32 (C, C8a of quinazoline), 128.94 (2CH, meta to NO2 of 4-nitrobenzyl), 
125.73 (CH of triazole), 125.39 (CH, C6 of quinazoline), 123.79 (2CH, ortho to NO2 of 4-nitrobenzyl), 122.35 (C, 
C4a of quinazoline), 118.96 (CH, C7 of quinazoline), 113.54 (CH, C5 of quinazoline), 60.09 (CH2 between O and 
triazole), 55.84 (CH3, OMe), 51.84 (CH2 of 4-nitrobenzyl). LC-MS: 392.37 [M]. HRMS–ESI (m/z) [M+Na]+ calcd 
for C19H16N6NaO4: 415.11252, found 415.1126, [M+K]+ calcd for C19H16KN6O4: 431.08646, found 431.0861. 
2-((1-(2,6-Dichlorobenzyl)-1H-1,2,3-triazol-4-yl)methoxy)-8-methoxyquinazoline (11j). Reaction of 15 (25 mg, 
0.11 mmol) with 16j (23.57 mg, 0.11 mmol) gave 11j: 29.3 mg, 60% yield. mp 186-188 °C; FT-IR (KBr, cm-1): 
3002, 1578, 1426, 1268, 1166, 1114, 1016, 758. 1H NMR (300 MHz, CDCl3): δ 9.19 (s, 1H, H-quinazoline), 7.85 
(br s, 1H, H-triazole), 7.44 (dd, J 8.2, 1.7 Hz, 1H, H-C7 of quinazoline), 7.42-7.36 (m, 3H, 2H ortho to Cl at 7.38 
ppm and H-C6 of quinazoline at 7.40 ppm), 7.29 (dd, J 9.1, 6.8 Hz, 1H, H meta to Cl), 7.19 (dd, J 7.3, 1.7 Hz, 1H, 
H-C5 of quinazoline), 5.85 (s, 2H, CH2 of 2,6-dichlorobenzyl), 5.70 (d, J 0.6 Hz, 2H, CH2 between O and triazole), 
4.03 (s, 3H, CH3, OMe). 13C NMR (75 MHz, CDCl3): δ 163.61 (CH, α to N of quinazoline), 161.50 (C, C2 of 
quinazoline), 153.73 (C, C8 of quinazoline), 143.62 (C of triazole), 143.53 (C, C8a of quinazoline), 136.85 (2C, α 
to Cl), 131.05 (CH, meta to Cl), 130.08 (C, β to Cl), 128.87 (2CH, ortho to Cl), 125.23 (CH, C6 of quinazoline), 
123.76 (CH of triazole), 122.78 (C, C4a of quinazoline), 118.89 (CH, C7 of quinazoline), 112.71 (CH, C5 of 
quinazoline), 61.39 (CH2 between O and triazole), 56.19 (CH3, OMe), 49.03 (CH2 of 2,6-dichlorobenzyl). LC-MS: 
416.26 [M]. HRMS–ESI (m/z) [M+Na]+ calcd for C19H1535Cl2N5NaO2: 438.04950, found 438.0495, [M+K]+ calcd 
for C19H1535Cl2KN5O2: 454.02344, found 454.0229. 
 
Cytotoxicity studies 
Cell culture.  Skin normal fibroblastic cells are purchased from Lonza (Basel, Switzerland), HuH7, Caco-2, MDA-
MB-231, HCT116, PC3, MCF7 and NCI-H727 cancer cell lines were obtained from the ECACC collection (Porton 
Down, UK). Cells are grown at 37°C, 5% CO2 in ECACC recommended media: DMEM for HuH7, MDA-MB-231 
and fibroblast, EMEM for MCF7 and CaCo-2, McCoy’s for HCT116 and RPMI for PC3 and NCI-H727. All culture 
media are supplemented by 10% of FBS, 1% of penicillin-streptomycin and 2 mM glutamine. 
Cytotoxic assay. Chemicals are solubilized in DMSO at a concentration of 10 mM (stock solution) and diluted 
in culture medium to the desired final concentrations. The dose effect cytotoxic assay of chemical is 
performed at 25 µM. Cells are plated in 96 wells plates (4000 cells/well). Twenty-four hours after seeding, cells 
are exposed to chemicals. After 48h of treatment, cells are washed in PBS and fixed in cooled 90% ethanol/5% 
acetic acid for 20 minutes and the nuclei are stained with Hoechst 33342 (B2261 Sigma). Image acquisition and 
analysis are performed using a Cellomics ArrayScan VTI/HCS Reader (ThermoScientific). The survival 
percentages are calculated as the percentage of cell number after compound treatment over cell number after 
DMSO treatment. 
Protein kinase assays 
Kinase enzymatic activities were assayed in 384-well plates using the ADP-Glo assay kit (Promega, Madison, 
WI) according to the recommendations of the manufacturer. This assay is a luminescent ADP detection assay 
that provides a homogeneous and high-throughput screening method to measure kinase activity by 
quantifying the amount of ADP produced during a kinase reaction. Briefly, the reactions were carried out in a 
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final volume of 6 µl for 30 min at 30°C in the following buffer: 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 25 mM 
Tris-HCl pH 7.5, 50 µg/ml heparin; with either protein or peptide as substrate in the presence of 10 µM ATP. 
After stopping the kinase reaction, Kinase Detection Reagent was added for one hour at RT. The transmitted 
signal was then measured using an Envision microplate luminometer (PerkinElmer, Waltham, MA) and 
expressed in Relative Light Unit (RLU). HsCDK5/p25 (human, recombinant, expressed in bacteria) was assayed 
on 0.8 µg/µl of histone H1 as substrate. HsCDK9/CyclinT (human, recombinant, expressed by baculovirus in Sf9 
insect cells) was assayed on 0.27 µg/µl of the following peptide: YSPTSPSYSPTSPSYSPTSPSKKKK, as substrate. 
HsGSK3β (human, recombinant, expressed by baculovirus in Sf9 insect cells) was assayed on 0.010 µg/µl of GS-
1 peptide, a GSK-3-selective substrate (YRRAAVPPSPSLSRHSSPHQSpEDEEE). HsCK1ε (human, recombinant, 
expressed by baculovirus in Sf9 insect cells) was assayed on 0.022 µg/µl of the following peptide: 
RRKHAAIGSpAYSITA (“Sp” stands for phosphorylated serine) as CK1-specific substrate. RnDYRK1A-kd (Rattus 
norvegicus, kinase domain aa 1 to 499, expressed in bacteria, DNA vector kindly provided by Dr. W. Becker, 
Aachen, Germany) was assayed on 0.033 μg/µl of the following peptide: KKISGRLSPIMTEQ as substrate. 
MmCLK1 (from Mus musculus, recombinant, expressed in bacteria) was assayed on 0.027 μg/µl of the 
following peptide: GRSRSRSRSRSR as substrate. HsPim-1 (human proto-oncogene, recombinant, expressed in 
bacteria) was assayed on 0.8 µg/µl of histone H1 (Sigma #H5505) as substrate. HsHaspin-kd (human, kinase 
domain, amino acids 470 to 798, recombinant, expressed in bacteria) was assayed on 0.007 µg/µl of Histone 
H3 (1-21) peptide (ARTKQTARKSTGGKAPRKQLA) as substrate. Peptide substrates were obtained from 
Proteogenix (Schiltigheim, France). 
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